Details
- Autor(en) / Beteiligte
- Titel
- Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
- Ist Teil von
- Cancers, 2021-11, Vol.13 (23), p.5994
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- A metastatic state of breast cancer (MBC) affects hundreds of thousands of women worldwide. In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) MBC, cyclin-dependent kinase (CDK)4/6 inhibitors can improve the progression-free survival (PFS), as well as the overall survival (OS), in selected patients and have been established as first- and second-line therapies. However, as MBC remains uncurable, resistance to CDK4/6 inhibitors occurs and requires alternative treatment approaches. Data on targeted therapy continue to mature, and the number of publications has been constantly rising. This review provides a summary and update on the clinical relevance, patient selection, ongoing trials of CDK4/6 inhibitors, and further targeted therapy options. It focuses on clinical aspects and practicability, as well as adverse events and patient-reported outcomes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2072-6694eISSN: 2072-6694DOI: 10.3390/cancers13235994Titel-ID: cdi_doaj_primary_oai_doaj_org_article_7cba76c28bc84404b8d1c19fb874b127
- Format
- –
- Schlagworte
- Adverse events, Breast cancer, Cancer therapies, CDK4/6 inhibitor, Cell cycle, Cell division, Chemotherapy, Clinical aspects, Clinical trials, Cyclin-dependent kinase 4, Cyclin-dependent kinases, Endocrine therapy, Enzymes, Epidermal growth factor, ErbB-2 protein, Estrogens, HR-positive breast cancer, Kinases, Medical prognosis, Metastases, Metastasis, metastatic breast cancer, Patients, PI3K inhibitor, quality of life in MBC, Review, Survival, targeted therapy, Womens health